Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 173   

Articles published

GSK 1,342.00 +3.00 (0.22%)
price chart
2 Numbers That Could Make GlaxoSmithKline plc A Spectacular Buy
The business has seen sales in China collapse. And concern about the long-term effect that the corruption case will have on future revenue growth has weighed heavily on GlaxoSmithKline for many months now. So news last month that the case had been ...
Related articles »  
GlaxoSmithKline plc Is Becoming More Attractive By The Day
GlaxoSmithKline plc's (LSE: GSK) share price is falling again today, which is great news, as at these prices the company is a steal.
Related articles »  
Beat The FTSE 100 With SABMiller plc, GlaxoSmithKline plc And British ...
With the FTSE 100 having fallen by over 8% during the last month, beating the returns on the index has become a priority for a number of UK investors.
Related articles »  
What This Top Dividend Portfolio Is Holding Now: HSBC Holdings plc ...
GlaxoSmithKline is in the midst of a bribery scandal. It isn't the first company to face this kind of situation, and it won't be the last.
Related articles »  
This May Be Your Last Chance To Buy Diageo plc, GlaxoSmithKline plc And ...
There's no denying that Diageo (LSE: DGE) has underperformed this year. Concerns about the company's growth have spooked investors and sales within China have been hit hard by the government's anti-extravagance measures.
Related articles »  
GlaxoSmithKline PLC vs AstraZeneca PLC: Which Is The Better Dividend Play?
AstraZeneca So, what is the future of pharma? With the patents of so many blockbuster drugs expiring, are pharmaceutical companies destined to decline?
What Happens If Pfizer Inc. Doesn't Come Back For AstraZeneca plc?  The Motley Fool UK
Related articles »  
What Management Would Prefer You Didn't Know About GlaxoSmithKline plc
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has unfortunately gone one step too far on a number of occasions. The actions of its representatives in China have been put under the spotlight, and now more allegations are emerging from the Middle East.
Zacks Reaffirms Underperform Rating for GlaxoSmithKline plc (GSK)
Zacks reaffirmed their underperform rating on shares of GlaxoSmithKline plc (NYSE:GSK) in a research note issued to investors on Tuesday.
GSK Bribery Conviction Signals Increased Risks In China  Law360 (subscription)
Related articles »  
Can Dividend Stock GlaxoSmithKline plc Bounce Back?
Given the widespread nature of this problem, Western authorities have taken a keen interest in the activities of their biopharmaceutical companies both abroad and at home.
Related articles »  
GlaxoSmithKline plc Receives "Equal Weight" Rating from Barclays (GSK)
Barclays reaffirmed their equal weight rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Thursday.
Deutsche Bank Reiterates "Hold" Rating for GlaxoSmithKline plc (GSK)  Watch List News (press release)
GlaxoSmithKline plc's "Hold" Rating Reaffirmed at Baader ...  WKRB News
Related articles »